Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 535Uterine Cervical Neoplasms 249Fallopian Tube Neoplasms 239Endometrial Neoplasms 142Carcinoma, Ovarian Epithelial 135Breast Neoplasms 101Neoplasms 74Carcinoma, Non-Small-Cell Lung 70Colorectal Neoplasms 53Uterine Cervical Dysplasia 49Papillomavirus Infections 49Neoplasm Metastasis 48Pancreatic Neoplasms 46Melanoma 44Uterine Neoplasms 43Prostatic Neoplasms 41Urinary Bladder Neoplasms 40Lung Neoplasms 40Stomach Neoplasms 38Peritoneal Neoplasms 37Recurrence 36Carcinoma, Renal Cell 35Triple Negative Breast Neoplasms 33Head and Neck Neoplasms 32Esophageal Neoplasms 31Small Cell Lung Carcinoma 30Sarcoma 28Vulvar Neoplasms 26Vaginal Neoplasms 24Testicular Neoplasms 22

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ovarian × Gynecologic × Clear all
NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

AstraZeneca

Phase 2 Completed
298 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡